Literature DB >> 24034415

How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.

Sofia Carvalhana1, Jorge Leitão, Ana C Alves, Mafalda Bourbon, Helena Cortez-Pinto.   

Abstract

BACKGROUND & AIMS: Liver steatosis measurement by controlled attenuation parameter (CAP) is a non-invasive method for diagnosing steatosis, based on transient elastography. Its usefulness as screening procedure for hepatic steatosis in general population has not been previously evaluated. The aim of this study was to evaluate the diagnostic accuracy of CAP and fatty liver index (FLI) for detection and quantification of steatosis in general population.
METHODS: Recruitment was done from a prospective epidemiological study of the general adult population. Steatosis was evaluated using CAP, FLI and ultrasound (US). Steatosis scored according to Hamaguchi's US scoring, from 0 (S0) to 6 (S6) points. Hepatic steatosis defined by score ≥2 (S≥2) and moderate/severe steatosis by score ≥4 (S≥4). Performance of CAP and FLI for diagnosing steatosis compared with US was assessed using areas under receiver operating characteristic curves (AUROC).
RESULTS: From 219 consecutive individuals studied, 13 (5.9%) excluded because of failure/unreliable liver stiffness measurements. Steatosis prevalence: S≥2 38.4% and S≥4 12.1%. CAP significantly correlated with steatosis (ρ = 0.73, P < 0.0001), steatosis score (ρ = 0.76; P < 0.0001), FLI (ρ = 0.69), waist circumference (ρ = 0.62), body mass index (ρ = 0.55), triglyceride (ρ = 0.49), HOMA-IR (ρ = 0.26), alcohol consumption (ρ = 0.24) and cholesterol (ρ = 0.19), not with liver stiffness measurements. Using CAP and FLI, AUROC's were 0.94 (95% CI 0.91-0.97, P < 0.001) and 0.91 for S≥2; 0.95 (95% CI 0.90-0.99, P < 0.001) and 0.93 for S≥4 respectively. Optimal cut-off value of CAP and FLI were 243 dB/m and 48 for S≥2; 303.5 dB/m and 62 for S≥4 respectively.
CONCLUSION: Controlled attenuation parameter and FLI seem promising tools for screening and steatosis quantification in the general population. Larger studies are needed for validation.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  controlled attenuation parameter; fatty liver; fibroscan; general population; hepatic steatosis; liver stiffness

Mesh:

Substances:

Year:  2013        PMID: 24034415     DOI: 10.1111/liv.12305

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  17 in total

1.  Screening for non-alcoholic fatty liver disease in children and adolescents with type 1 diabetes mellitus: a cross-sectional analysis.

Authors:  Sebastian Kummer; Dirk Klee; Gerald Kircheis; Michael Friedt; Joerg Schaper; Dieter Häussinger; Ertan Mayatepek; Thomas Meissner
Journal:  Eur J Pediatr       Date:  2017-02-17       Impact factor: 3.183

2.  Risk Assessment of Hepatocellular Carcinoma in General Population by Liver Stiffness in Combination with Controlled Attenuation Parameter using Transient Elastography: A Cross Sectional Study.

Authors:  Takaaki Sugihara; Masahiko Koda; Tomomitsu Matono; Kinya Okamoto; Yoshikazu Murawaki; Hajime Isomoto; Shiho Tokunaga
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

3.  Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea.

Authors:  Young Eun Chon; Kyu Sik Jung; Kwang Joon Kim; Dong Jin Joo; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Seung Up Kim
Journal:  Dig Dis Sci       Date:  2014-08-14       Impact factor: 3.199

4.  Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance?

Authors:  Mariana Verdelho Machado
Journal:  GE Port J Gastroenterol       Date:  2017-07-04

5.  Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B.

Authors:  Duo-Duo Lv; You-Juan Wang; Meng-Lan Wang; En-Qiang Chen; Ya-Chao Tao; Dong-Mei Zhang; Hong Tang
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

Review 6.  Non-invasive diagnosis of hepatic steatosis.

Authors:  Christiane Stern; Laurent Castera
Journal:  Hepatol Int       Date:  2016-10-25       Impact factor: 6.047

7.  Ideal cardiovascular health predicts lower risk of abnormal liver enzymes levels in the Chilean National Health Survey (2009-2010).

Authors:  Antonio García-Hermoso; Anthony C Hackney; Robinson Ramírez-Vélez
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

8.  Serum Fetuin-A Associated With Fatty Liver Index, Early Indicator of Nonalcoholic Fatty Liver Disease: A Strobe-Compliant Article.

Authors:  Ya Huang; Xiaolin Huang; Lin Ding; Po Wang; Kui Peng; Ying Chen; Meng Dai; Di Zhang; Min Xu; Yufang Bi; Weiqing Wang
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

9.  ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population.

Authors:  Jinghua Wang; Chengfu Xu; Yunhao Xun; Zhenya Lu; Junping Shi; Chaohui Yu; Youming Li
Journal:  Sci Rep       Date:  2015-11-16       Impact factor: 4.379

10.  Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease.

Authors:  Jem Ma Ahn; Yong-Han Paik; Sin Yeong Min; Ju Yeon Cho; Won Sohn; Dong Hyun Sinn; Geum-Youn Gwak; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.